Ace the Case: Spotlighting Pediatric Diagnosis and Treatment of Rett Syndrome
This activity is supported by an independent educational grant from Acadia Pharmaceuticals
Click Here to Manage Email Alerts
Course Update: As of March 13, 2023, trofinetide received FDA approval for the treatment of Rett Syndrome in adults and children 2 years of age and older, becoming the first agent approved by the FDA for this indication.
Release Date: 1/15/2023
Expiration Date: 1/15/2024
Estimated Time to Complete Activity: 30 minutes
This educational activity will utilize two case studies to highlight practical approaches and clinical decision-making for the diagnosis and treatment of Rett Syndrome.
Jointly provided by Partners for Advancing Clinical Education (PACE) and BRAINWeek
For additional information about the accreditation of this activity, please visit https://partnersed.com
This activity is supported by an independent educational grant from Acadia Pharmaceuticals.
Arthur (Art) Beisang, MD
St. George’s University School of Medicine
This activity is intended for an audience of pediatricians, nurse practitioners, and physician assistants who care for patients with Rett Syndrome.
Upon completion of this activity, participants should be able to:
- Summarize the background of Rett Syndrome
- Discuss the quality-of-life of pediatric patients who have Rett Syndrome
- Recognize important considerations when providing a differential diagnosis in patients with Rett Syndrome
- Describe the emerging treatment options for Rett Syndrome
Faculty and Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Dr. Beisang is a consultant/advisor/speaker for Acadia.
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The BRAINWeek planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and BRAINWeek. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Participation
In order to receive credit, participants must complete the activity in its entirety. Participants must complete the posttest along with the credit application and evaluation form.
There are no fees for participating in this activity.